PHD inhibitor

This page covers all PHD inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Prolyl hydroxylase domain-containing proteins (PHD).

Targets

Prolyl hydroxylase domain-containing proteins (PHD)

Phase 3 pipeline (1)

• Desidustat Oral Tablet · Zydus Lifesciences Limited · Hematology
  Desidustat inhibits prolyl hydroxylase domain-containing protein (PHD) enzymes to stabilize hypoxia-inducible factor (HIF) and increase endogenous erythropoietin production.

Patent intelligence

• phd inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates